FC25: Setting Sights Higher With New and Emerging TYK2 Inhibitors for Psoriasis: An Online Activity

Have you seen the TYK-talk about TYK2? Psoriasis experts Dr. April Armstrong, Dr. Bruce Strober, and Dr. Ron Vender discuss the efficacy and safety of upcoming TYK2 inhibitor treatment options and what it means for patients at the 2025 Fall Clinical Dermatology Conference®.

“TYK2 inhibitors are actually quite different from the other Janus kinase inhibitors that target JAK 1, 2, and 3 that we have for other indications...When we look at the safety profiles, it's pretty reassuring.” – April W. Armstrong, MD, MPH

FC25: Setting Sights Higher With New and Emerging TYK2 Inhibitors for Psoriasis

This activity is supported by educational grants from Takeda Pharmaceuticals U.S.A., Inc.